Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Business Overview: Neurocrine is a neuroscience company focused on discovering and developing novel therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases. The company operates in a single industry segment and relies heavily on strategic alliances with major pharmaceutical partners (Janssen, Novartis, Eli Lilly, Wyeth-Ayerst) for funding, development, and commercialization. As of the reporting date, the company had no commercial product sales and incurred a cumulative deficit of approximately $25 million.
Key Financial Metrics
| Metric (in thousands) | 1998 | 1997 | 1996 |
|---|---|---|---|
| Total Revenues | $16,037 | $26,144 | $19,216 |
| Net Income (Loss) | $(19,955) | $5,127 | $5,874 |
| Operating Expenses | $33,307 | $24,422 | $16,266 |
| Research & Development Expenses | $21,803 | $18,758 | $12,569 |
| Cash & Short-Term Investments | $62,670 | $75,092 | $69,920 |
| Long-Term Debt & Capital Leases | $2,247 | $722 | $847 |
| Accumulated Deficit | $(24,850) | $(4,895) | $(10,022) |
Liquidity: The company held $62.7 million in cash, cash equivalents, and short-term investments as of December 31, 1998. Management believes existing resources, combined with interest income and future collaboration payments, will satisfy funding requirements through the year 2000.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 39% from $26.1 million in 1997 to $16.0 million in 1998. This decline was primarily due to the completion of the sponsored research portion of the Janssen collaboration in 1997, the absence of a one-time research support payment from Eli Lilly, and the timing of milestone achievements.
- Net Loss: The company swung from a net income of $5.1 million in 1997 to a net loss of $20.0 million in 1998. This was driven by increased operating expenses and a significant non-cash write-off.
- Acquisition Write-off: In 1998, the company recorded a $4.9 million write-off for acquired in-process research and development (IPR&D) and licenses. This included the acquisition of Northwest NeuroLogic, Inc. (NNL) and licenses for insomnia and brain cancer technologies, which had not yet reached technological feasibility.
- Investment Write-down: The company recorded a $3.8 million write-down in the value of its investment in Neuroscience Pharma, Inc. (NPI), a Canadian affiliate, following the discontinuation of the DHEA Neurosteroid program.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Neurocrine expects to incur substantial operating losses in future periods as clinical development efforts expand. The company anticipates R&D expenditures of approximately $15.6 million in the upcoming fiscal year for specific programs (EAATs, MCR, IL-4 Fusion Toxin, and NBI-34060). The company has no commercial product sales and does not expect to generate product revenues in the foreseeable future; revenue will continue to depend on strategic alliances.
Key Risks and Contingencies
- Dependence on Partners: The company is heavily dependent on corporate partners (Janssen, Novartis, Lilly, Wyeth-Ayerst) for funding, clinical trial execution, and commercialization. Termination of these agreements would have a material adverse effect.
- Patent Disputes: A third-party patent application regarding CRF receptor antagonists (a key program with Janssen) may predate the company's filing. If the third-party patent issues, it could block commercialization or require a license, potentially delaying milestone payments.
- Regulatory Approval: All products require FDA approval. Early clinical trial results are not predictive of later-stage success, and failure in clinical trials would halt development and revenue streams.
- Year 2000 Compliance: The company is in the remediation phase for Year 2000 issues, with an estimated total project cost of $175,000. While most IT systems are compliant, some scientific equipment requires replacement or modification.
Investor Verification Checklist
- Collaboration Status: Verify the current status of Phase II trials with Janssen (anxiety/depression) and Novartis (multiple sclerosis), as these are the primary drivers of future milestone revenue.
- Patent Litigation: Monitor the outcome of discussions regarding the third-party patent application for CRF receptor antagonists to assess potential commercialization barriers.
- Cash Burn Rate: Confirm that the $62.7 million cash balance is sufficient to fund operations through 2000 given the projected increase in R&D spending.
- Program Discontinuation: Review the impact of the discontinued DHEA Neurosteroid program on the NPI affiliate and future royalty expectations.
- Wyeth-Ayerst Agreement: Assess the terms and funding schedule of the new collaboration agreement signed in March 1999 for EAATs, which was a subsequent event not fully reflected in 1998 financials.